Several types of arthritis fall under the JIA heading. This inflammation begins before patients reach the age of 16 years, and may involve one or many joints and cause other symptoms such as fevers, rash, and eye inflammation.
The Mystery of IVIg
Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.
RA Treatment May Be Beneficial Even After Patients Meet Remission Criteria
An analysis of wrist MRIs from participants in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) clinical trial indicates that patients continue to show joint inflammation even after two years of early aggressive therapy.
Rheum with a View
Panush’s perspectives on selections from the literature
Could Lipids Be a Key to Control Inflammation?
Presenters spotlight complex relationship between lipid metabolism, atherosclerosis, and autoimmune disorders
No Clear Connection Between Inflammation & Disease Progression in AS
TNF blockers decrease symptoms but seem to have little impact on structural damage
The Expanded Role of the Inflammasome in Human Disease
Exploring advances, evaluating what remains to be done
Cardiovascular Disease Risk High in RA Patients
High incidence of metabolic disease and concurrent inflammation increases risk
Immune System No Longer Autonomous?
Evolving model has implications for novel therapies
Exploring the Complement System in Human Disease
Novel disease associations revealed by whole genome screens
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »